Medicinal Cannabis – The Green Fairy Phenomenon

2021 ◽  
Author(s):  
Onyekachi Raymond ◽  
Mary Jane McCarthy ◽  
Jess Baker ◽  
Helen Poulsen
Keyword(s):  
Medicinal Cannabis

scholarly journals Foreign investment in emerging legal medicinal cannabis markets: the Jamaica case study

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Marta Rychert ◽  
Machel Anthony Emanuel ◽  
Chris Wilkins
Keyword(s):  
Civil Society ◽  
Foreign Investment ◽  
Production Efficiency ◽  
Production Quality ◽  
Small Scale ◽  
Organic Cultivation ◽  
Enhanced Production ◽  
Political Interference ◽  
Medicinal Cannabis ◽  
The Impact

Abstract Introduction The establishment of a legal market for medicinal cannabis under the Dangerous Drugs Amendment Act 2015 has positioned Jamaica at the forefront of cannabis law reform in the developing world. Many local cannabis businesses have attracted investment from overseas, including from Canada, US and Europe. Aim To explore the opportunities and risks of foreign investment in an emerging domestic legal cannabis market in a developing country. Methods Thematic analysis of semi-structured face-to-face interviews with 22 key informants (KIs) from the Jamaican government, local cannabis industry, academia and civil society, and field observations of legal and illegal cannabis cultivators. Results KIs from the Jamaican public agencies and domestic cannabis entrepreneurs saw foreign investment as an essential source of capital to finance the start-up costs of legal cannabis businesses. Local cannabis entrepreneurs prioritised investors with the greatest financial resources, brand reputation and export networks. They also considered how allied an investor was with their business vision (e.g., organic cultivation, medical vs. recreational). The key benefits of partnering with a foreign investor included transfer of technical knowledge and financial capital, which enhanced production, quality assurance and seed-to-sale tracking. Some KIs expressed concern over investors’ focus on increasing production efficiency and scale at the expense of funding research and development (R&D) and clinical trials. KIs from the local industry, government agencies and civil society highlighted the risks of ‘predatory’ shareholder agreements and domestic political interference. Concerns were raised about the impact of foreign investment on the diversity of the domestic cannabis sector in Jamaica, including the commitment to transition traditional illegal small-scale cannabis cultivators to the legal sector. Conclusion While foreign investment has facilitated the commercialisation of the cannabis sector in Jamaica, regulatory measures are also needed to protect the domestic industry and support the transition of small-scale illegal cultivators to the legal regime. Foreign investments may alter the economic, social and political determinants of health in transitioning from illegal to legal cannabis market economy.

Defining the trials nurses’ role in operationalising a medicinal cannabis clinical trial

2021 ◽  
Author(s):  
Valentina Razmovski-Naumovski ◽  
Penny A. West ◽  
Frances Bellemore ◽  
Naomi Byfieldt ◽  
Douglas Bellamy ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Nurses Role ◽  
Medicinal Cannabis

Prescribing medicinal cannabis

2018 ◽  
Vol 16 (12) ◽  
pp. 577-577
Author(s):  
Deborah Robertson
Keyword(s):  
Medicinal Cannabis

scholarly journals Effect of Medicinal Cannabis Therapy (Mct) On Severity of Chronic Low Back Pain, Sciatica and Lumbar Range of Motion

2016 ◽  
Vol 1 (2) ◽  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Range Of Motion ◽  
Chronic Low Back Pain ◽  
Sagittal Plane ◽  
Treatment Protocol ◽  
Adjunctive Treatment ◽  
Low Back ◽  
Patient Reported ◽  
Medicinal Cannabis

Background: Anecdotal evidence indicates the possible efficacy of cannabis use as an adjunctive treatment in chronic low back pain. The purpose of the current study was to assess the results of treatment of patients suffering from chronic low back pain by medicinal cannabis (MCT). Methods: A cohort of 46 patients was followed for a minimum of twelve months. They were evaluated at baseline prior to MCT, 3 months later when MCT was begun and up to 12 months of MCT by patient reported outcome questionnaire (SF-12), visual analogue scale (VAS) and the Brief Pain Inventory (BPI), back specific function was assessed using the Oswestry score, range of motion was measured using the Saunders digital inclinometer. Opiate use was assessed using pharmacy dispensation records at baseline and after 12 months of MCT. Inclusion criteria included: age over 25 years, sciatica with documented treatment for at least 12 months, evidence on CT or MRI scan of disc herniation or spinal stenosis, failure of at least two narcotic drugs, and consent to use medicinal cannabis. Exclusion criteria included evidence of bone cancer, evidence of diabetic neuropathy, and evidence of prior psychotic reactions. Treatment protocol: Cannabis usage was at a fixed dosage of 20 grams per month, dose increase was considered at least after 6 months of treatment. The cannabis was smoked at a recommended rate of 4 dosages per day. Results: After 12 months of MCT BPI VAS decreased from 8.4 ± 1.4 to 2.0 ± 2.0; SF12-PCS improved from 47 ± 14 to 55 ± 12; SF12-MCS improved from 44 ± 6 to 50 ± 10; and sagittal plane active range of motion improved from 34º ± 8º degrees to 48º ± 8º, In conclusion, short term usage of smoked medicinal cannabis appear to improve both physical and mental function while decreasing pain levels of chronic low back pain sufferers.

scholarly journals Comparison of effects of medicinal cannabis or standard palliative care on quality of life of patients with cholangiocarcinoma in Northeast Thailand

F1000Research ◽  
2022 ◽  
Vol 11 ◽  
pp. 20
Author(s):  
Narisara Phansila ◽  
Chaiyasit Sittiwet ◽  
Ranee Wongkongdech
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Rank Test ◽  
Northeast Thailand ◽  
Care Clinic ◽  
Early Access ◽  
Signed Rank Test ◽  
Medicinal Cannabis ◽  
Pre Treatment

Background: Cholangiocarcinoma (CCA) has a poor prognosis and is a major cause of mortality and suffering in Thailand’s Northeastern (Isaan) Region.   Methods: This prospective cohort study aimed to compare the health-related quality of life (HRQoL) among 72 newly diagnosed CCA patients; 42 patients who received cannabis treatment (CT) and 30 patients who received a standard palliative care treatment (ST). The study was carried out between 1st September 2019 to 31st October 2020.  Data were collected from patients from oncology clinics of six hospitals in five provinces of northeast Thailand. The HRQoL was measured at baseline, and at 2 and 4 months after diagnosis by the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaires QLQ-C30, and QLQ-BIL21. The Mann-Whitney U-test was performed to compare quality of life scores between the two patient groups and Wilcoxon signed rank test was performed to compare within groups QoL scores at pre-treatment, and 2 and 4 month follow-ups. Results: Global health status and functional scales, for both groups were high at pre-treatment. At 2 and 4 month follow-up, CT group patients had consistent statistically significantly better Palliative Performance Scale (PPS), and QoL scores, and many symptom scores than the ST group.   Conclusions: Medicinal cannabis may increase QoL for advanced CCA patients. Our findings support the importance of early access to palliative cannabis care clinic before the terminal and acceleration phase close to death.

Sign in / Sign up

Export Citation Format

Share Document